21st Austria weekly - Valneva (31/05/2024)

02.06.2024

Valneva: Valneva, a specialty vaccine company, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending authorization of Valneva’s single-dose vaccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The European Commission (EC) will review the CHMP recommendation, and a decision on the marketing authorization application of IXCHIQ® in the European Union (EU), Norway, Liechtenstein and Iceland is expected in the third quarter of 2024. If approved, it will become the first chikungunya vaccine available in Europe to address this unmet medical need. In accordance with the International Reliance Procedure (IRP), Valneva is also preparing a Marketing Authorization Application (MAA) for submission to the UK Medicines and Healthcare products Regulatory Agency (MHRA). Juan Carlos Jaramillo, Chief Medical Officer of Valneva, commented, “This positive CHMP opinion marks a crucial milestone toward introducing a preventative solution against chikungunya in the EU. In recent years, climate change has caused the Aedes mosquito, a known carrier of chikungunya and dengue viruses, to spread to areas in Europe that were previously unaffected. It is critical to provide a vaccine solution not only to European travelers going to endemic chikungunya areas, such as South America or Africa, but also to the local European populations experiencing invasive mosquito attacks. The broader we can make this vaccine accessible, the better we will mitigate the burden of this debilitating illness, and we would like to thank our partner, CEPI, for supporting us in this endeavor.”
Valneva: weekly performance: 6.03%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (31/05/2024)


Partners









latest 21st Austria

21st Austria weekly - Valneva (31/05/2024)


02.06.2024, 1849 Zeichen



Valneva: Valneva, a specialty vaccine company, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending authorization of Valneva’s single-dose vaccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The European Commission (EC) will review the CHMP recommendation, and a decision on the marketing authorization application of IXCHIQ® in the European Union (EU), Norway, Liechtenstein and Iceland is expected in the third quarter of 2024. If approved, it will become the first chikungunya vaccine available in Europe to address this unmet medical need. In accordance with the International Reliance Procedure (IRP), Valneva is also preparing a Marketing Authorization Application (MAA) for submission to the UK Medicines and Healthcare products Regulatory Agency (MHRA). Juan Carlos Jaramillo, Chief Medical Officer of Valneva, commented, “This positive CHMP opinion marks a crucial milestone toward introducing a preventative solution against chikungunya in the EU. In recent years, climate change has caused the Aedes mosquito, a known carrier of chikungunya and dengue viruses, to spread to areas in Europe that were previously unaffected. It is critical to provide a vaccine solution not only to European travelers going to endemic chikungunya areas, such as South America or Africa, but also to the local European populations experiencing invasive mosquito attacks. The broader we can make this vaccine accessible, the better we will mitigate the burden of this debilitating illness, and we would like to thank our partner, CEPI, for supporting us in this endeavor.”
Valneva: weekly performance: 6.03%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (31/05/2024)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

kapitalmarkt-stimme.at daily voice 99/365: Wie das am Österreichischen Aktientag dann mit der Free Tombola ablaufen wird




 

Bildnachweis

Aktien auf dem Radar:Flughafen Wien, Addiko Bank, DO&CO, Austriacard Holdings AG, RHI Magnesita, Zumtobel, Bawag, AT&S, CA Immo, Kapsch TrafficCom, Marinomed Biotech, Mayr-Melnhof, OMV, Polytec Group, RBI, Rosenbauer, SBO, Semperit, Oberbank AG Stamm, Agrana, Erste Group, FACC, Wienerberger, Amag, Österreichische Post, Telekom Austria, Uniqa, VIG, ATX.


Random Partner

EVN
Die EVN ist ein internationales, börsennotiertes Energie- und Umweltdienstleistungsunternehmen mit Sitz in Niederösterreich und bietet in ihrem Heimmarkt auf Basis modernster Infrastruktur Strom, Gas, Wärme, Trinkwasserver- sowie Abwasserentsorgung und thermische Abfallverwertung „aus einer Hand“. Das Energiegeschäft im Ausland umfasst den Stromverkauf an Endkund*innen in Deutschland, Bulgarien und Nordmazedonien, den Gasverkauf an Endkund*innen in Kroatien, sowie die Stromproduktion in Nordmazedonien, Bulgarien, Albanien und Deutschland.

>> Besuchen Sie 60 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten


h